{"id":4268,"date":"2024-07-11T05:30:48","date_gmt":"2024-07-11T09:30:48","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/"},"modified":"2026-09-24T00:05:51","modified_gmt":"2026-09-24T04:05:51","slug":"gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/","title":{"rendered":"GenSight Biologics lance une lettre d&rsquo;information pour les investisseurs particuliers"},"content":{"rendered":"\n<strong>Paris, France, le 11 juillet 2024<\/strong>, <strong>7h30 CEST<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, a annonc\u00e9 aujourd&rsquo;hui la diffusion du premier num\u00e9ro de sa lettre d&rsquo;information, destin\u00e9e aux investisseurs particuliers en France. Cette lettre d\u2019information, trimestrielle, sera publi\u00e9e en fran\u00e7ais et sera disponible sur le site web de la soci\u00e9t\u00e9 ainsi que sur inscription.\n\n\u00ab\u00a0<em>Nous sommes ravis de mettre en place ce nouveau mode de communication avec nos investisseurs particuliers, qui nous permettra de les informer des \u00e9volutions de la soci\u00e9t\u00e9, de leur pr\u00e9senter notre \u00e9quipe mais \u00e9galement d&rsquo;aborder de fa\u00e7on plus approfondie des sujets trait\u00e9s dans nos canaux plus formels tels que les communiqu\u00e9s de presse<\/em>\u00a0\u00bb, a d\u00e9clar\u00e9 <strong>Laurence Rodriguez, <\/strong>Directrice G\u00e9n\u00e9rale de GenSight Biologics. \u00ab\u00a0<em>C\u2019est \u00e9galement un t\u00e9moignage de notre gratitude pour le soutien sans faille, qui nous a \u00e9t\u00e9 signifi\u00e9 au fil des ans, de la part de nos investisseurs<\/em>.\u00a0\u00bb\n\nLe premier num\u00e9ro, publi\u00e9 aujourd&rsquo;hui, comporte :\n<ul>\n \t<li>Un \u00e9ditorial de la Directrice G\u00e9n\u00e9rale<\/li>\n \t<li>Les derniers articles de presse concernant l&rsquo;entreprise<\/li>\n \t<li>Un calendrier des conf\u00e9rences au cours desquelles des donn\u00e9es sur les futurs traitements de la soci\u00e9t\u00e9 ont \u00e9t\u00e9 ou seront pr\u00e9sent\u00e9es<\/li>\n \t<li>Des informations sur un prix prestigieux, d\u00e9cern\u00e9 au Professeur Jos\u00e9-Alain Sahel et \u00e0 son coll\u00e8gue Botond Roska, co-fondateurs de la soci\u00e9t\u00e9, r\u00e9compensant le travail pionnier en optog\u00e9n\u00e9tique,<\/li>\n \t<li>Un regard plus approfondi sur la fabrication de LUMEVOQ<sup>\u00ae<\/sup><\/li>\n \t<li>Les chiffres cl\u00e9s de l&rsquo;entreprise<\/li>\n<\/ul>\nCette lettre est disponible dans l&rsquo;onglet \u00ab\u00a0Investisseurs\u00a0\u00bb du site web de l&rsquo;entreprise, <a href=\"https:\/\/www.gensight-biologics.com\/fr\/lettre-aux-actionnaires\">https:\/\/www.gensight-biologics.com\/fr\/lettre-aux-actionnaires<\/a>, qui contient \u00e9galement les modalit\u00e9s d&rsquo;inscription.\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 11 juillet 2024, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, a annonc\u00e9 aujourd&rsquo;hui la diffusion du premier num\u00e9ro de sa lettre [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76],"post-year":[],"class_list":["post-4268","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics lance une lettre d&#039;information pour les investisseurs particuliers - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics lance une lettre d&#039;information pour les investisseurs particuliers - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 11 juillet 2024, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, a annonc\u00e9 aujourd&rsquo;hui la diffusion du premier num\u00e9ro de sa lettre [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-11T09:30:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:51+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics lance une lettre d&rsquo;information pour les investisseurs particuliers\",\"datePublished\":\"2024-07-11T09:30:48+00:00\",\"dateModified\":\"2026-09-24T04:05:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/\"},\"wordCount\":335,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/\",\"name\":\"GenSight Biologics lance une lettre d'information pour les investisseurs particuliers - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2024-07-11T09:30:48+00:00\",\"dateModified\":\"2026-09-24T04:05:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/07\\\/11\\\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics lance une lettre d&rsquo;information pour les investisseurs particuliers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics lance une lettre d'information pour les investisseurs particuliers - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics lance une lettre d'information pour les investisseurs particuliers - GenSight Biologics","og_description":"Paris, France, le 11 juillet 2024, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, a annonc\u00e9 aujourd&rsquo;hui la diffusion du premier num\u00e9ro de sa lettre [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/","og_site_name":"GenSight Biologics","article_published_time":"2024-07-11T09:30:48+00:00","article_modified_time":"2026-09-24T04:05:51+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics lance une lettre d&rsquo;information pour les investisseurs particuliers","datePublished":"2024-07-11T09:30:48+00:00","dateModified":"2026-09-24T04:05:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/"},"wordCount":335,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/","name":"GenSight Biologics lance une lettre d'information pour les investisseurs particuliers - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2024-07-11T09:30:48+00:00","dateModified":"2026-09-24T04:05:51+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/07\/11\/gensight-biologics-lance-une-lettre-dinformation-pour-les-investisseurs-particuliers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics lance une lettre d&rsquo;information pour les investisseurs particuliers"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4268"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4268\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4268"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4268"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4268"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4268"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}